Ardelyx (ARDX) Total Current Liabilities (2013 - 2026)
Ardelyx (ARDX) reported Total Current Liabilities of $109.6 million for Q1 2026, up 44.47% on a YoY basis from $75.8 million in Q1 2025, and up 23.66% quarter-over-quarter from $88.6 million in Q4 2025.
Ardelyx (ARDX) Total Current Liabilities (2013 - 2026) Analysis & Trends
Ardelyx has reported Total Current Liabilities for 14 years, with the latest figure at $109.6 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 44.47% year-over-year to $109.6 million; the trailing twelve-month figure through Mar 2026 stood at $109.6 million (up 44.47% YoY), and the FY2025 full-year result was $88.6 million, up 13.84% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $109.6 million, up from $88.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $109.6 million in Q1 2026, with the low at $43.5 million in Q3 2023.
- Historically, Total Current Liabilities has averaged $67.0 million across 5 years, with a median of $63.1 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities declined 24.45% — and 2024, when it surged 61.96%.
- Ardelyx's Total Current Liabilities stood at $65.6 million in 2022, then decreased by 23.18% to $50.4 million in 2023, then soared by 54.45% to $77.8 million in 2024, then climbed by 13.84% to $88.6 million in 2025, then increased by 23.66% to $109.6 million in 2026.
- The last three Total Current Liabilities figures came in at $109.6 million (Q1 2026), $88.6 million (Q4 2025), and $83.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 109.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109.57 Mn |
| Dec 31, 2025 | 88.61 Mn |
| Sep 30, 2025 | 83.39 Mn |
| Jun 30, 2025 | 81.72 Mn |
| Mar 31, 2025 | 75.84 Mn |
| Dec 31, 2024 | 77.83 Mn |
| Sep 30, 2024 | 70.50 Mn |
| Jun 30, 2024 | 62.44 Mn |
| Mar 31, 2024 | 56.90 Mn |
| Dec 31, 2023 | 50.39 Mn |
| Sep 30, 2023 | 43.53 Mn |
| Jun 30, 2023 | 61.69 Mn |
| Mar 31, 2023 | 63.06 Mn |
| Dec 31, 2022 | 65.60 Mn |
| Sep 30, 2022 | 51.95 Mn |
| Jun 30, 2022 | 48.70 Mn |
| Mar 31, 2022 | 47.84 Mn |
| Dec 31, 2021 | 52.82 Mn |
| Sep 30, 2021 | 68.77 Mn |
| Jun 30, 2021 | 57.79 Mn |